Universal G6PD Screening: A Retrospective Chart Review

Abstract

Get full access to this article

View all access options for this article.

References

Cappellini

Fiorelli

Glucose-6-phosphate dehydrogenase deficiency. The Lancet. 2008;371(9606):64-74. doi:10.1016/S0140-6736(08)60073-2.

Glader

. Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency. UpToDate. Accessed May 31, 2023. https://www.uptodate.com/contents/diagnosis-and-management-of-glucose-6-phosphate-dehydrogenase-g6pd-deficiency?search=g6pd+def&;source=search_result&;selectedTitle=1~150&;usage_type=default&;display_rank=.

Wright

Davis

Joseph

, et al Eliminating race-based medicine. Pediatrics. 2022;150(1):e2022057998. doi:10.1542/peds.2022-057998.

Smith

. Race-based medicine is wrong. How should physicians oppose it? American Medical Association. Accessed May 31, 2023.https://www.ama-assn.org/delivering-care/health-equity/race-based-medicine-wrong-how-should-physicians-oppose-it.

Mersha

Abebe

Self-reported race/ethnicity in the age of genomic research: its potential impact on understanding health disparities. Hum Genomics. 2015;9:1. doi:10.1186/s40246-014-0023-x.

Nkhoma

Poole

Vannappagari

Hall

Beutler

The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009;42(3):267-278. doi:10.1016/j.bcmd.2008.12.005.

Michele Caggana

Shulman

. G-6-PD newborn screening, newborn screening mandated in NYS public health law ¬ß2500-a and 2500-f. Accessed May 11, 2022. https://www.health.ny.gov/professionals/hospital_administrator/letters/2022/docs/dal_22-03.pdf.

Collins

FS.

What we do and don’t know about “race,” “ethnicity,” genetics, and health at the dawn of the genome era. Nat Genet. 2004;36(11 Suppl):S13-S15. doi:10.1038/ng1436.

Roberts

DE.

What’s wrong with race-based medicine?

Faculty Scholarship at Penn Carey Law. 2011;435. Accessed May 11, 2023. https://scholarship.law.upenn.edu/faculty_scholarship/435.

10.

Bakkum

Verdonk

Thomas

, et al A clinical pharmacology and therapeutics teacher’s guide to race-based medicine, inclusivity, and diversity. Clin Pharmacol Ther. 2023;113(3):600-606. doi:10.1002/cpt.2786.

11.

American Academy of Pediatrics Board of Directors and Executive Committee. AAP perspective: race-based medicine. Pediatrics. 2021;148(4):e2021053829. doi:10.1542/peds.2021-053829.

12.

Trent

Dooley

Dougé

; Section on Adolescent Health; Council on Community Pediatrics; Committee on Adolescence. The impact of racism on child and adolescent health. Pediatrics. 2019;144(2):e20191765. doi:10.1542/peds.2019-1765.

13.

Genetics Co. Committee opinion: carrier screening for genetic conditions. American College of Obstetricians and Gynecologists. March 2017. Accessed May 11, 2023. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/03/carrier-screening-for-genetic-conditions.

14.

Grosse

Boyle

Botkin

, et al Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep. 2004;53(RR-13):1-36.

15.

National Newborn Screening and Genetics Resource Center. National Newborn Screening Report 2000. San Antonio, TX: National Newborn Screening and Genetics Resource Center; 2003. Accessed May 31, 2023. http://genes-r-us.uthscsa.edu/resources/newborn/00chapters.html.

16.

Delfavero

Jnah

Newberry

Glucose-6-phosphate dehydrogenase deficiency and the benefits of early screening. Neonatal Network. 2020;39(5):270-282. doi:10.1891/0730-0832.39.5.270.

17.

Watchko

Kaplan

Stark

Stevenson

Bhutani

VK.

Should we screen newborns for glucose-6-phosphate dehydrogenase deficiency in the United States?

J Perinatol. 2013;33(7):499-504. doi:10.1038/jp.2013.14.